List of Excipients in Branded Drug OXYMETAZOLINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing OXYMETAZOLINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Sun Pharmaceutical Industries Inc	oxymetazoline hydrochloride	51672-1405	ANHYDROUS CITRIC ACID
Sun Pharmaceutical Industries Inc	oxymetazoline hydrochloride	51672-1405	BUTYLATED HYDROXYTOLUENE
Sun Pharmaceutical Industries Inc	oxymetazoline hydrochloride	51672-1405	CETEARETH-25
Sun Pharmaceutical Industries Inc	oxymetazoline hydrochloride	51672-1405	CETEARETH-6

What are the Most Frequently-Used Excipients in OXYMETAZOLINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	BUTYLATED HYDROXYTOLUENE
1	CETEARETH-25
1	CETEARETH-6

Oxymetazoline Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Oxymetazoline hydrochloride has two commercially distinct platforms: nasal decongestants and ophthalmic products for acquired blepharoptosis. The active ingredient is inexpensive and well established, so commercial differentiation depends on excipient selection, delivery-device performance, preservative strategy, dosing convenience, tolerability, and regulatory positioning.

The strongest opportunity is in ophthalmic reformulation. Upneeq, the first FDA-approved oxymetazoline ophthalmic product, established a prescription market for acquired blepharoptosis. Nasal products remain high-volume but highly competitive and largely commoditized. Excipient innovation can support premium products in both segments, but it is more likely to create defensible value in ophthalmic delivery than in standard nasal sprays.

What is oxymetazoline hydrochloride used for?

Oxymetazoline hydrochloride is a direct alpha-adrenergic agonist that produces local vasoconstriction. FDA-approved uses include temporary relief of nasal congestion and treatment of acquired blepharoptosis through topical ophthalmic administration.

Product segment	Representative product	Strength	Route	Regulatory status
Nasal decongestant	Afrin and store-brand products	Commonly 0.05%	Intranasal spray	OTC
Pediatric nasal products	Children’s oxymetazoline products	Commonly 0.025%	Intranasal spray	OTC
Acquired blepharoptosis	Upneeq	0.1%	Ophthalmic solution	Prescription
Compounded or development products	Various	Variable	Nasal, ophthalmic, specialty delivery	Depends on product

Oxymetazoline nasal products are generally intended for short-term use because prolonged use can cause rebound congestion, also known as rhinitis medicamentosa. Upneeq is administered once daily to the affected eye or eyes, according to FDA labeling.[1]

What excipients are used in oxymetazoline hydrochloride products?

The excipient system depends on the route of administration, target tissue, packaging, and preservative strategy.

Ophthalmic excipients

Upneeq contains oxymetazoline hydrochloride 0.1% in an aqueous ophthalmic solution. The FDA label identifies the inactive ingredients as benzalkonium chloride, boric acid, citric acid monohydrate, sodium citrate dihydrate, sodium chloride, and water for injection.[1]

The formulation functions can be summarized as follows:

Excipient	Primary function
Benzalkonium chloride	Antimicrobial preservative
Boric acid	Buffering and tonicity support
Citric acid monohydrate	pH adjustment and buffer component
Sodium citrate dihydrate	Buffering and pH control
Sodium chloride	Isotonicity adjustment
Water for injection	Vehicle

The key technical issues are ocular tolerability, pH, osmolality, preservative exposure, extractables and leachables, and chemical stability. Oxymetazoline hydrochloride is a potent sympathomimetic, so minimizing unnecessary ocular irritation is commercially important even when the active ingredient is effective.

Nasal excipients

Typical oxymetazoline nasal sprays use an aqueous vehicle with sodium chloride or another tonicity modifier, a buffering system, and a preservative where the container design requires multidose microbial protection. Common excipient classes include:

• Sodium chloride or alternative tonicity agents
• Phosphate, citrate, or borate buffers
• Benzalkonium chloride or other preservatives
• Chelating agents such as disodium edetate
• Solubilizers and wetting agents
• Viscosity modifiers
• Purified water

Nasal formulations must balance sprayability, droplet-size distribution, mucosal residence time, comfort, and microbial control. Higher viscosity may increase residence time but can impair pump performance, produce a less acceptable sensory profile, or alter dose deposition.

Which excipients create the greatest commercial differentiation?

Preservative-free delivery, mucoadhesion, and device-compatible viscosity control offer the clearest differentiation opportunities.

Preservative-free ophthalmic formulations

Benzalkonium chloride is effective and widely used, but chronic ocular exposure can contribute to epithelial toxicity and ocular-surface irritation in susceptible patients. A preservative-free oxymetazoline product could target patients with dry eye, ocular-surface disease, contact-lens use, or repeated long-term treatment.

The commercial tradeoff is packaging cost. A preservative-free product generally requires single-dose vials, a multidose preservative-free container, or a validated sterile dispensing system. These formats increase component cost and may require more complex container-closure validation.

Buffered low-irritation systems

A citrate-borate or alternative low-capacity buffer can be optimized to maintain oxymetazoline stability while reducing stinging. The target is a formulation with acceptable pH and osmolality that avoids excessive buffering capacity. A poorly selected buffer can increase discomfort even when the nominal pH is physiologically acceptable.

Mucoadhesive nasal systems

Nasal products can use low concentrations of polymers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers, or selected polyvinyl alcohol grades to increase residence time. The formulation must preserve pump dose uniformity and avoid excessive viscosity.

Potential benefits include:

• Reduced post-dose runoff
• Longer nasal residence
• Lower dosing frequency
• Improved perception of sustained relief
• Potentially lower active concentration

These claims require clinical support. A longer residence time alone does not establish superior decongestant efficacy.

Spray-performance excipients

The pump and formulation operate as a single delivery system. Surface tension, viscosity, density, and formulation rheology influence plume geometry and droplet size. A formulation that produces a narrow, reproducible plume may improve deposition in the intended nasal region and reduce throat runoff.

For generic and OTC development, the device is a major source of complexity. A compositionally simple formulation can still fail comparative performance testing if the pump, actuator, container, or priming behavior differs from the reference product.

What formulation patents protect oxymetazoline hydrochloride products?

Formulation patents may protect the composition, concentration range, pH, preservative system, delivery device, dosing regimen, or method of treating a specific condition. The active ingredient itself is long established and generally does not provide meaningful composition-of-matter exclusivity.

Upneeq patent and exclusivity position

Upneeq was approved by the FDA in July 2020 for acquired blepharoptosis in adults.[1] Its regulatory differentiation comes from the ophthalmic route, concentration, clinical data, and approved method of use rather than from new chemical-entity status.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity for the marketed product.[2] Patent coverage should be assessed by reviewing:

1. Orange Book-listed patents for the specific Upneeq product.
2. Patent families covering ophthalmic oxymetazoline compositions.
3. Patents covering dosing for acquired blepharoptosis.
4. Device and container-closure patents.
5. Continuation and divisional applications.
6. Litigation and settlement records in the U.S. District Court and Federal Circuit.

Because patent listings and legal status can change through delisting, expiration, terminal disclaimers, reexamination, and litigation, a product-specific freedom-to-operate analysis should use the current Orange Book and USPTO records rather than relying on a single patent database.

Nasal formulation protection

Afrin and similar products are generally mature OTC products. Protection is more likely to arise from brand, packaging, trade dress, device performance, and formulation know-how than from enforceable basic composition patents. A new nasal product could seek protection for:

• A preservative-free multidose container
• A polymeric sustained-residence formulation
• A specific pH and buffer system
• A low-dose formulation with equivalent efficacy
• A combination product
• A metered-dose pump with improved plume characteristics
• A formulation that reduces sensory irritation

Patents covering excipient ranges can be difficult to enforce commercially if competitors can design around the claimed concentration or substitute a functionally equivalent excipient.

When does oxymetazoline hydrochloride lose exclusivity?

Nasal oxymetazoline has already lost basic market exclusivity. Multiple OTC generic and store-brand products compete with branded Afrin.

Upneeq does not benefit from conventional NCE exclusivity because oxymetazoline is an old active ingredient. The product could receive regulatory exclusivity linked to new clinical investigations, but any such period tied to the 2020 approval would have ended or substantially elapsed by 2023. The remaining entry barrier is therefore primarily patent, regulatory, manufacturing, device, and commercial execution.

Exclusivity category	Relevance to oxymetazoline
New chemical entity	Not expected for this established active
Standard generic competition	Already present for nasal products
3-year clinical-investigation exclusivity	Potentially relevant to the 2020 Upneeq approval
Orphan exclusivity	Not generally associated with Upneeq’s approved indication
Patent exclusivity	Product-specific; requires current Orange Book review
Device or formulation protection	Potentially material for ophthalmic and specialty products

Which companies are challenging oxymetazoline products?

Nasal competition comes from major consumer-health companies, private-label manufacturers, contract manufacturers, and pharmacy chains. The market includes branded and store-brand products using oxymetazoline hydrochloride at established concentrations.

The competitive structure is different for Upneeq. Potential challengers would likely pursue an abbreviated new drug application if the product and reference-product requirements support an ANDA pathway. A 505(b)(2) application could be more appropriate for a materially different formulation, device, concentration, or indication.

A Paragraph IV challenge would require a generic applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The principal practical barriers are:

• Demonstrating pharmaceutical equivalence and bioequivalence
• Matching ophthalmic product quality and sterility
• Establishing device performance
• Addressing listed method-of-use patents
• Managing formulation differences
• Avoiding infringement of composition or dosing claims

No specific Paragraph IV litigation or settlement should be treated as established without a current review of FDA litigation listings, court dockets, and the Orange Book.

What FDA pathway applies to new oxymetazoline formulations?

The pathway depends on the proposed product and the reference product.

ANDA pathway

An ANDA is most attractive for a product that matches the reference product in dosage form, strength, route, active ingredient, and key pharmaceutical characteristics. For an ophthalmic generic, the sponsor must address sterility, impurities, container closure, delivery performance, and bioequivalence requirements.

A preservative-free product or a materially different container may fall outside a straightforward ANDA strategy, depending on FDA requirements.

505(b)(2) pathway

A 505(b)(2) application may support:

• A new ophthalmic concentration
• A new route or dosage form
• A new delivery device
• A modified excipient system
• A new indication
• A sustained-release or enhanced-residence formulation

The sponsor may rely partly on existing FDA findings while generating bridging clinical, pharmacokinetic, local-tolerance, or efficacy data.

OTC monograph pathway

Nasal decongestant products may be developed under the FDA OTC monograph framework when they conform to applicable monograph requirements. A formulation that introduces a new active combination, unusual delivery technology, or new therapeutic claim may require an NDA or another regulatory pathway.

What commercial opportunities exist for oxymetazoline excipient innovation?

1. Preservative-free ophthalmic oxymetazoline

This is the most credible premium opportunity. The target customer is a patient who needs repeated use but has ocular-surface sensitivity. A single-dose format could support higher pricing, although packaging waste and manufacturing costs would rise.

2. Extended-duration nasal decongestants

A mucoadhesive formulation could support once-daily positioning or reduce runoff. The regulatory value depends on demonstrating clinically meaningful duration rather than only laboratory retention.

3. Lower-irritation nasal sprays

A formulation with optimized pH, osmolality, buffer capacity, and preservative exposure could compete on comfort. Consumer preference studies may be commercially useful, but therapeutic claims require appropriate clinical evidence.

4. Combination products

Oxymetazoline could be paired with agents addressing allergic or inflammatory symptoms. Combination products increase market potential but add compatibility, clinical, labeling, and patent complexity. They also may create more direct competition with established allergy products.

5. Specialty ocular indications

The vasoconstrictive mechanism could support research in additional eyelid or ocular indications, but each new claim would require clinical validation. The regulatory and patent value would depend on whether the indication is sufficiently differentiated from acquired blepharoptosis.

6. Device-led products

Airless multidose dispensers, preservative-free systems, dose counters, improved actuators, and child-resistant packaging can create commercial differentiation. Device patents and design controls may provide a stronger barrier than a narrow excipient claim.

How strong is the oxymetazoline patent estate?

The estate is strong for the established active ingredient as a manufacturing and supply platform, but weak for basic molecule-level exclusivity because oxymetazoline is old. Patent strength is product-specific.

Estate component	Commercial strength
Basic oxymetazoline molecule	Low
Standard nasal aqueous formulation	Low to moderate
Branded OTC positioning	Moderate through brand and distribution
Ophthalmic 0.1% formulation	Moderate, subject to current patent claims
Acquired blepharoptosis method of use	Potentially meaningful
Preservative-free delivery	Potentially meaningful if technically specific
Device and container system	Moderate to strong if difficult to design around
Manufacturing know-how	Often important but not publicly visible

The most defensible strategy combines formulation, device, manufacturing process, and method-of-use claims. A single excipient-range patent is less secure because competitors can often alter the buffer, preservative, polymer, or concentration while maintaining similar product performance.

What manufacturing and intellectual-property barriers affect market entry?

Sterile ophthalmic manufacturing is the primary operational barrier for Upneeq-type products. A sponsor needs validated compounding, sterile filling, container-closure integrity, particulate control, preservative effectiveness where applicable, and stability data.

The major technical risks include:

• Oxymetazoline degradation or impurity formation
• Adsorption to container or device components
• Incompatibility with elastomers and plastics
• Inconsistent delivered volume
• Preservative loss during storage
• Microbial contamination
• Ocular irritation
• Changes in plume or droplet size for nasal products

Manufacturing know-how may protect a product even when patent protection is limited. A robust process for controlling impurities, filling small ophthalmic doses, and maintaining dose uniformity can reduce the practical threat from nominally substitutable products.

How does oxymetazoline compare with competing alpha-adrenergic products?

Attribute	Oxymetazoline	Phenylephrine	Naphazoline	Brimonidine
Main established use	Nasal congestion; acquired blepharoptosis	Nasal congestion; ocular redness	Nasal congestion; ocular redness	Ocular redness; other ophthalmic uses
Ophthalmic blepharoptosis approval	Yes, Upneeq	No comparable approved product	No comparable approved product	No comparable approved product
Nasal OTC maturity	High	High	Established	Limited
Premium ophthalmic opportunity	High relative to nasal segment	Limited	Limited	Competitive but indication-dependent
Main differentiation lever	Formulation, device, indication	Combination and symptom positioning	Ocular comfort and legacy brand	Ocular pharmacology and formulation

Oxymetazoline’s commercial advantage is the combination of a mature, low-cost active ingredient with a differentiated ophthalmic indication. Its weakness is the absence of molecule-level exclusivity and the ease of substitution in nasal products.

What generic launch risks exist?

A nasal generic launch faces low scientific risk but high price and distribution pressure. An ophthalmic generic faces higher development and manufacturing risk, but it could target a smaller market with greater price separation.

Potential launch scenarios include:

1. A direct nasal OTC private-label launch using an established formulation.
2. An ophthalmic ANDA that closely matches Upneeq.
3. A 505(b)(2) product using preservative-free packaging or a different dosing regimen.
4. A branded specialty product built around comfort, duration, or device usability.
5. A combination nasal product competing in allergy or sinus-care channels.

The highest-value opportunity is likely a clinically supported ophthalmic reformulation with improved tolerability or preservative-free delivery. The lowest-risk opportunity is a standard nasal private-label product, but margins are likely to be limited.

What is the geographic opportunity for oxymetazoline products?

The United States is the most developed opportunity because it has both a large OTC nasal market and an FDA-approved ophthalmic product for acquired blepharoptosis. Outside the United States, regulatory classification, approved indications, prescription status, and patent rights must be assessed country by country.

Geographic expansion opportunities include:

• OTC nasal products in markets with established decongestant use
• Prescription ophthalmic products in jurisdictions recognizing acquired blepharoptosis as a treatable indication
• Licensing of sterile ophthalmic manufacturing and distribution rights
• Private-label supply for pharmacy and consumer-health channels
• Regional device partnerships for preservative-free delivery

International value depends less on the active ingredient and more on local regulatory approval, reimbursement, intellectual-property status, and distribution economics.

Key Takeaways

• Oxymetazoline hydrochloride is a mature active ingredient with limited basic-molecule exclusivity.
• Nasal products are commoditized; formulation and device improvements may support only modest differentiation.
• The strongest commercial opportunity is ophthalmic oxymetazoline for acquired blepharoptosis.
• Preservative-free packaging, ocular comfort, low-irritation buffers, and improved delivery systems are priority excipient strategies.
• Upneeq’s 2020 FDA approval created a prescription ophthalmic market but did not create new-chemical-entity exclusivity.
• Generic entry risk depends on current Orange Book listings, formulation patents, method-of-use claims, device rights, and the selected ANDA or 505(b)(2) pathway.
• Sterile ophthalmic manufacturing and container-closure performance are major practical barriers.
• A defensible product should combine excipient, device, manufacturing, and method-of-use protection rather than rely on a narrow composition claim.

FAQs About Oxymetazoline Hydrochloride Excipient and Commercial Strategy

Can benzalkonium chloride be removed from oxymetazoline ophthalmic products?

Yes. Removal is technically feasible, but the product would require a preservative-free packaging system or another validated microbial-control strategy. The change may require a new formulation-development and regulatory strategy.

Is oxymetazoline hydrochloride suitable for sustained-release nasal delivery?

Yes, but the formulation must maintain dose uniformity, pump performance, mucosal tolerability, and acceptable sensory properties. Polymer-based residence-time enhancement is a plausible development route.

Can a company patent an oxymetazoline buffer system?

Yes. Patentability depends on novelty, non-obviousness, claim scope, and demonstrated technical effect. A patent is stronger when the buffer system produces a measurable stability, tolerability, or delivery benefit.

Is Upneeq eligible for generic competition?

Potentially. An applicant could pursue an ANDA if it can satisfy the applicable reference-product and equivalence requirements. A materially different formulation or device may require a 505(b)(2) application.

What is the most valuable oxymetazoline product opportunity?

A preservative-free or low-irritation ophthalmic product for acquired blepharoptosis is the strongest differentiated opportunity. Standard nasal oxymetazoline remains easier to launch but is more exposed to price competition.

References

1. U.S. Food and Drug Administration. (2020). Upneeq: Oxymetazoline hydrochloride ophthalmic solution, 0.1% prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Nasal decongestant drug products for over-the-counter human use. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug product labeling and regulatory information for oxymetazoline hydrochloride products. FDA.